Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, November 15, 2021

FDA OKs trial to test stroke treatment in distal brain regions

 WHOM in your stroke hospital is specifically following and implementing research results into stroke protocols? NO SUCH PERSON, YOU DON'T HAVE A STROKE HOSPITAL, FIRE THEM ALL.

FDA OKs trial to test stroke treatment in distal brain regions

The FDA has granted investigational device exemption approval to Rapid Medical for a trial to expand stroke treatment to distal brain regions, according to a press release.

The DISTALS study, a randomized controlled trial seeking to examine the safety and effectiveness of distal thrombectomy, will involve Rapid Medical’s Tigertriever 13, the smallest thrombectomy device available.

“We're especially pleased to receive unprecedented FDA IDE approval for a study with DISTALS’ focus," principal investigator Jeffrey Saver, MD, FAHA, professor of neurology and director of the Comprehensive Stroke and Vascular Neurology Program at UCLA, said in the release. "With the ever-growing benefits of mechanical thrombectomy, we hope to offer better recoveries to a much broader patient population.”

At present, less than 10% of patients who had ischemic stroke received mechanical thrombectomy, which has been shown to significantly improve outcomes, according to the release. Tigertriever 13 has been used in approximately 1,500 patients in Europe and the Middle East. With data from the DISTALS Study, Rapid Medical aims to reach an additional 25% to 40% of stroke patients with this treatment form. The intervention targets far areas of the brain, including M3 blood vessels and allows intervention within 24 hours from onset of symptoms.

"The DISTALS trial is critical for the field of interventional stroke therapy,” co-coordinating investigator David Fiorella, MD, PhD, director of the Cerebrovascular Center at Stony Brook University Medical Center in New York, said in the release. "It potentially allows us to offer thrombectomy to an additional large group of stroke patients who may benefit substantially.”

No comments:

Post a Comment